Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01398670
Recruitment Status : Withdrawn (Study was not initiated)
First Posted : July 20, 2011
Last Update Posted : January 25, 2013
Information provided by (Responsible Party):

Brief Summary:
This is a randomized, parallel group comparison of the immunogenicity safety of Wockhardt's Insulin analogue Lispro and lispro Mix with Eli Lilly's Insulin analogue Humalog® and Humalog® Mix in patients with Type 1 Diabetes Mellitus

Condition or disease Intervention/treatment Phase
Type I Diabetes Biological: Insulin Lispro Phase 3

Detailed Description:
To evaluate and compare the Immunogenicity safety of Wockhardt's Insulin analogue Lispro and lispro Mix with Eli Lilly's Insulin analogue Humalog® and Humalog® Mix in Type I Diabetic patients.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of the Immunogenicity of Wockhardt's Insulin Analogue Lispro and Lispro Mix With Eli Lilly's Insulin Analogue Humalog® and Humalog® Mix in Type 1 Diabetic Patients
Study Start Date : February 2012
Estimated Primary Completion Date : March 2013
Estimated Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Lispro arm
Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
Biological: Insulin Lispro

a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50

The drugs would be administered subcutaneously

Active Comparator: Humalog® arm
Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
Biological: Insulin Lispro

Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50

The drugs would be administered subcutaneously

Primary Outcome Measures :
  1. Change in HbA1c [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Percentage change in the immunogenic response [ Time Frame: 6 months ]
  2. Correlation of the immunogenicity with hypoglycemia [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients who understand the nature of the study and are willing to provide written informed consent.
  2. Patients who have been pre-diagnosed as cases of type-1 diabetes for a period not less than 1 year
  3. Male or Female Patients ≥ 18 and < 55 years of age.
  4. Patients with body mass index (BMI) of 18.0 to 30.0 kg/m2
  5. Patients who are cooperative, reliable, and agree to have regular injections of insulin and are willing to comply with protocol procedures.
  6. Ability to use the self glucose-monitoring device and to self inject insulin.

Exclusion Criteria:

  1. Females who are pregnant or lactating, or not practicing adequate contraception.
  2. A Patient with compromised hepatic or renal function
  3. A Patient who is an employee of the Investigator, or a patient who has a direct involvement with the trial or other trials under the direction of the Investigator.
  4. A Patient who has been treated with other investigational agent or devices within the previous 30 days, has planned use of investigational drugs or devices, or has been previously randomized in this trial.
  5. A Patient with history or evidence of allergy to insulin preparations.
  6. A Patients who is currently receiving or has received, within the last year, any immunomodulator medications.
  7. Patients unlikely to comply with the study protocol e.g. unable to return periodically for subsequent visits.
  8. Patients who are judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01398670

Sponsors and Collaborators
Study Director: Dr.Rasendrakumar Jha Wockhardt

Responsible Party: Wockhardt Identifier: NCT01398670     History of Changes
Other Study ID Numbers: P3-LIS-IMSFDA-01
First Posted: July 20, 2011    Key Record Dates
Last Update Posted: January 25, 2013
Last Verified: January 2013

Keywords provided by Wockhardt:
Type I Diabetes
Wockhardt's Insulin analogue Lispro
Humalog Mix
Phase 3

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin Lispro
Insulin, Isophane
Biphasic Insulins
Hypoglycemic Agents
Physiological Effects of Drugs